Alec Stranahan
Stock Analyst at B of A Securities
(0.83)
# 3,973
Out of 5,045 analysts
31
Total ratings
41.67%
Success rate
-24.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $182 → $255 | $189.08 | +34.86% | 5 | Oct 17, 2025 | |
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $5.58 | +25.45% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $14.13 | -15.07% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $2.46 | -59.35% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $8.43 | -16.96% | 5 | Aug 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $23.80 | +76.47% | 1 | Mar 28, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $7.04 | +255.11% | 4 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $2.32 | +374.14% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $2.64 | +127.27% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $3.01 | +398.34% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $58.87 | -6.57% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $34.02 | -82.36% | 2 | Dec 29, 2022 |
Krystal Biotech
Oct 17, 2025
Maintains: Buy
Price Target: $182 → $255
Current: $189.08
Upside: +34.86%
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $5.58
Upside: +25.45%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $14.13
Upside: -15.07%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $2.46
Upside: -59.35%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $8.43
Upside: -16.96%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $23.80
Upside: +76.47%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $7.04
Upside: +255.11%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $2.32
Upside: +374.14%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $2.64
Upside: +127.27%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $3.01
Upside: +398.34%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $58.87
Upside: -6.57%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $34.02
Upside: -82.36%